Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal angiomyolipomata.

John J Bissler1, J Chris Kingswood

  • 1Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. john.bissler@cchmc.org

Kidney International
|August 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the self-report quantified Tuberous Sclerosis Complex-Associated Neuropsyciatric Disorders Checklist (TAND-SQ).

Orphanet journal of rare diseases·2025
Same author

Comparison of GFR estimation equations using creatinine, cystatin C, and their combination in pediatric hematology-oncology: no single equation is superior across subgroups.

Pediatric nephrology (Berlin, Germany)·2025
Same author

Role of Extracellular Vesicles in TSC Renal Cystogenesis.

International journal of molecular sciences·2025
Same author

Neuro-Ophthalmic Characteristics of Patients with Tuberous Sclerosis Complex at a Tertiary Care Referral Centre.

Neuro-ophthalmology (Aeolus Press)·2025
Same author

Concomitant Wilms tumor and autosomal dominant polycystic kidney disease.

Pediatric blood & cancer·2024
Same author

Tuberous Sclerosis Complex and the kidneys: what nephrologists need to know.

Jornal brasileiro de nefrologia·2024
Same journal

Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-storing histiocytosis causing severe acute kidney injury.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
See all related articles

Renal angiomyolipomata, common benign tumors, can be life-threatening, especially with tuberous sclerosis complex. Future drug therapies offer hope for managing these kidney lesions.

Area of Science:

  • Nephrology
  • Oncology
  • Genetics

Background:

  • Renal angiomyolipomata (RAML) affect over 10 million worldwide, with 10% also having tuberous sclerosis complex.
  • RAML can range from incidental findings to life-threatening conditions requiring intervention.
  • Current management prioritizes renal tissue preservation through observation, nephrectomy, or embolization.

Purpose of the Study:

  • To provide nephrologists with an update on the molecular biology of RAML.
  • To discuss the potential for future pharmacologic therapies for RAML.
  • To highlight the multidisciplinary approach needed for managing patients with RAML.

Main Methods:

  • Literature review of current research on RAML.
  • Analysis of molecular pathways involved in RAML development.

Related Experiment Videos

  • Discussion of emerging therapeutic strategies.

    • Main Results:

    • Ongoing basic science research is elucidating the molecular mechanisms of RAML.
    • Advances in understanding may lead to targeted drug therapies.
    • Multisystemic involvement necessitates collaboration among various medical specialists.

    Conclusions:

    • Pharmacologic treatment for RAML is a promising future direction.
    • Continued research into RAML biology is crucial for developing effective therapies.
    • Integrated care models are essential for patients with complex RAML presentations.